Acuta Capital Partners’s Akebia Therapeutics AKBA Stock Holding History

Acuta Capital Partners’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-698,825	Closed	-$7.28M	–	68
2016 Q4	$7.28M	Sell	698,825 -1,175	-0.2%	-$10.1K	2.71%	14
2016 Q3	$6.33M	Buy	700,000 +100,000	+17%	+$850K	2.38%	14
2016 Q2	$4.49M	Buy	600,000 +213,692	+55%	+$1.87M	2.16%	15
2016 Q1	$3.48M	Buy	+386,308	New	+$3.13M	1.95%	19

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acuta Capital Partners's AKBA Position: Q1 2017 in Review

Acuta Capital Partners sold out of Akebia Therapeutics (AKBA) in Q1 2017, closing a stake of 698,825 shares — an estimated $7.28M sold.

Acuta Capital Partners first reported a position in AKBA in Q1 2016 and held it in 4 quarters. The position peaked at $7.28M in Q4 2016. 89 funds tracked by Wall St. Rank hold AKBA as of Q1 2017.

Acuta Capital Partners reported no remaining Akebia Therapeutics position as of Q1 2017 after selling out during the quarter.
Acuta Capital Partners sold 698,825 Akebia Therapeutics shares in Q1 2017, an estimated $7.28M.
Acuta Capital Partners first reported a position in Akebia Therapeutics in Q1 2016 and held it in 4 quarters.
Acuta Capital Partners's Akebia Therapeutics position peaked at $7.28M in Q4 2016.
89 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2017.

Based on Acuta Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.